This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (232)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Dementias  • Quality of Care  • Evidence-Based Medicine  • Review  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Meta-analysis of Randomized Placebo-Controlled Trials

Lon S. Schneider, MD, MS; Karen S. Dagerman, MS; Philip Insel, MS

JAMA. 2005;294:1934-1943.

Context  Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease and other dementia; however, concerns have arisen about the increased risk for cerebrovascular adverse events, rapid cognitive decline, and mortality with their use.

Objective  To assess the evidence for increased mortality from atypical antipsychotic drug treatment for people with dementia.

Data Sources  MEDLINE (1966 to April 2005), the Cochrane Controlled Trials Register (2005, Issue 1), meetings presentations (1997-2004), and information from the sponsors were searched using the terms for atypical antipsychotic drugs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone), dementia, Alzheimer disease, and clinical trial.

Study Selection  Published and unpublished randomized placebo-controlled, parallel-group clinical trials of atypical antipsychotic drugs marketed in the United States to treat patients with Alzheimer disease or dementia were selected by consensus of the authors.

Data Extraction  Trials, baseline characteristics, outcomes, all-cause dropouts, and deaths were extracted by one reviewer; treatment exposure was obtained or estimated. Data were checked by a second reviewer.

Data Synthesis  Fifteen trials (9 unpublished), generally 10 to 12 weeks in duration, including 16 contrasts of atypical antipsychotic drugs with placebo met criteria (aripiprazole [n = 3], olanzapine [n = 5], quetiapine [n = 3], risperidone [n = 5]). A total of 3353 patients were randomized to study drug and 1757 were randomized to placebo. Outcomes were assessed using standard methods (with random- or fixed-effects models) to calculate odds ratios (ORs) and risk differences based on patients randomized and relative risks based on total exposure to treatment. There were no differences in dropouts. Death occurred more often among patients randomized to drugs (118 [3.5%] vs 40 [2.3%]. The OR by meta-analysis was 1.54; 95% confidence interval [CI], 1.06-2.23; P = .02; and risk difference was 0.01; 95% CI, 0.004-0.02; P = .01). Sensitivity analyses did not show evidence for differential risks for individual drugs, severity, sample selection, or diagnosis.

Conclusions  Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo. This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives. Individual patient analyses modeling survival and causes of death are needed.

Author Affiliations: Departments of Psychiatry and the Behavioral Sciences (Dr Schneider and Ms Dagerman), Neurology (Dr Schneider), and Department of Preventive Medicine (Mr Insel), Keck School of Medicine, and Leonard Davis School of Gerontology (Dr Schneider), University of Southern California, Los Angeles.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Harminder Sikand, Joyce Jaojoco, Leslie Linares, and Paul S. Phillips
JAMA. 2006;295(5):495.
EXTRACT | FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Sudeep S. Gill, Dallas Seitz, and Paula A. Rochon
JAMA. 2006;295(5):495-496.
EXTRACT | FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Karianne Hammerstrøm
JAMA. 2006;295(5):496.
EXTRACT | FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death—Reply
Lon S. Schneider, Karen S. Dagerman, and Philip Insel
JAMA. 2006;295(5):496-497.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Antipsychotic Drugs in Dementia: What Should Be Made of the Risks?
Peter V. Rabins and Constantine G. Lyketsos
JAMA. 2005;294(15):1963-1965.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline
Prodan et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1416-1417.
FULL TEXT  

The Assessment and Management of Delirium in Cancer Patients
Bush and Bruera
The Oncologist 2009;14:1039-1049.
ABSTRACT | FULL TEXT  

Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges
Crystal et al.
Health Aff (Millwood) 2009;28:w770-w781.
ABSTRACT | FULL TEXT  

Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study
Zheng et al.
Am. J. Psychiatry 2009;166:583-590.
ABSTRACT | FULL TEXT  

Dementia
Burns and Iliffe
BMJ 2009;338:b75-b75.
FULL TEXT  

Alzheimer's disease
Burns and Iliffe
BMJ 2009;338:b158-b158.
FULL TEXT  

Guidelines on antipsychotics for dementia: are we losing our minds?
Haw et al.
Psychiatr. Bull. 2009;33:57-60.
ABSTRACT | FULL TEXT  

Ask the Expert: Geriatric Psychiatry
Cheong
Focus 2009;7:36-37.
FULL TEXT  

Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease
Tangwongchai et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2009;23:593-601.
ABSTRACT  

Agitation and Delirium at the End of Life: "We Couldn't Manage Him"
Breitbart and Alici
JAMA 2008;300:2898-2910.
ABSTRACT | FULL TEXT  

Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease
Herrmann and Gauthier
CMAJ 2008;179:1279-1287.
ABSTRACT | FULL TEXT  

Dementia of the Alzheimer Type
Jalbert et al.
Epidemiol Rev 2008;30:15-34.
ABSTRACT | FULL TEXT  

Evaluating the association between clozapine and venous thromboembolism
Paciullo
Am J Health Syst Pharm 2008;65:1825-1829.
ABSTRACT | FULL TEXT  

Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study
Wood-Mitchell et al.
Age Ageing 2008;37:547-552.
ABSTRACT | FULL TEXT  

Concerns about health care warnings and their impact on prescribing behaviour
Katz
CMAJ 2008;179:405-406.
FULL TEXT  

Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis
Valiyeva et al.
CMAJ 2008;179:438-446.
ABSTRACT | FULL TEXT  

Antipsychotics for people with dementia
O'Brien
BMJ 2008;337:a602-a602.
FULL TEXT  

Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia
Rochon et al.
Arch Intern Med 2008;168:1090-1096.
ABSTRACT | FULL TEXT  

Who Are the New Users of Antipsychotic Medications?
Domino and Swartz
Psychiatr. Serv. 2008;59:507-514.
ABSTRACT | FULL TEXT  

New use of antipsychotic drugs in elderly people with dementia may increase the mortality risk
Kales
Evid. Based Ment. Health 2008;11:54-54.
FULL TEXT  

Five-year follow-up of an evidence-based prescribing intervention
Meagher et al.
Psychiatr. Bull. 2008;32:183-186.
ABSTRACT | FULL TEXT  

Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis
Maidment et al.
The Annals of Pharmacotherapy 2008;42:32-38.
ABSTRACT | FULL TEXT  

How safe are antipsychotics in dementia?
DTB 2007;45:81-85.
ABSTRACT | FULL TEXT  

Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck et al.
Arch Gen Psychiatry 2007;64:1259-1268.
ABSTRACT | FULL TEXT  

Rapid Eye Movement Sleep Behavior Disorder
Gugger and Wagner
The Annals of Pharmacotherapy 2007;41:1833-1841.
ABSTRACT | FULL TEXT  

Treatment of Neuropsychiatric Symptoms in Patients with Dementia
Yaffe
NEJM 2007;357:1441-1443.
FULL TEXT  

Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications
Kales et al.
Am. J. Psychiatry 2007;164:1568-1576.
ABSTRACT | FULL TEXT  

Survival of Ethnic Chinese With Alzheimer's Disease: A 5-Year Longitudinal Study in Taiwan
Tsai et al.
J Geriatr Psychiatry Neurol 2007;20:172-177.
ABSTRACT  

Dementia and Comorbidities: An Overview of Diagnosis and Management
Swanson and Carnahan
Journal of Pharmacy Practice 2007;20:296-317.
ABSTRACT  

Antipsychotic Medication Use in the Elderly Patient
Malone et al.
Journal of Pharmacy Practice 2007;20:318-326.
ABSTRACT  

The Importance of Diagnosing and Managing ICU Delirium
Pun and Ely
Chest 2007;132:624-636.
ABSTRACT | FULL TEXT  

Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill et al.
ANN INTERN MED 2007;146:775-786.
ABSTRACT | FULL TEXT  

Antipsychotic prescribing for behavioural and psychological symptoms of dementia
Soyinka and Lawley
Psychiatr. Bull. 2007;31:176-178.
ABSTRACT | FULL TEXT  

Dopamine Agonists and Valvular Heart Disease
Stephens et al.
NEJM 2007;356:1676-1680.
FULL TEXT  

Variation in Nursing Home Antipsychotic Prescribing Rates
Rochon et al.
Arch Intern Med 2007;167:676-683.
ABSTRACT | FULL TEXT  

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
Schneeweiss et al.
CMAJ 2007;176:627-632.
ABSTRACT | FULL TEXT  

Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Blaszczyk and Mathys
Journal of Pharmacy Practice 2007;20:13-28.
ABSTRACT  

Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics
Bettinger et al.
The Annals of Pharmacotherapy 2007;41:201-207.
ABSTRACT | FULL TEXT  

Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly
Beier
Am J Health Syst Pharm 2007;64:S9-S17.
ABSTRACT | FULL TEXT  

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study
Livingston et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:25-29.
ABSTRACT | FULL TEXT  

Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review.
Ayalon et al.
Arch Intern Med 2006;166:2182-2188.
ABSTRACT | FULL TEXT  

Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease.
Schneider et al.
NEJM 2006;355:1525-1538.
ABSTRACT | FULL TEXT  

Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning.
Friedman
Neurology 2006;67:564-566.
ABSTRACT | FULL TEXT  

Response to guidance on use of olanzapine and risperidone: a community-based study of primary and secondary care
Franks
Psychiatr. Bull. 2006;30:289-292.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Knight and Fihn
ANN INTERN MED 2006;145:52-61.
FULL TEXT  

Delirium in older persons.
Anton et al.
NEJM 2006;354:2509-2511.
FULL TEXT  

Why are doctors still prescribing neuroleptics?
Charlton
QJM 2006;99:417-420.
ABSTRACT | FULL TEXT  

Innovations: Geriatric Psychiatry: Diagnosis and Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease
Lavretsky and Nguyen
Psychiatr. Serv. 2006;57:617-619.
ABSTRACT | FULL TEXT  

Review: atypical antipsychotic drugs slightly increase mortality rates in elderly people with dementia.
Liperoti
Evid. Based Ment. Health 2006;9:54-54.
FULL TEXT  

ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2006;11:62-62.
FULL TEXT  

Delusions and hallucinations in Alzheimer disease.
Gill
Arch Neurol 2006;63:627-627.
FULL TEXT  

Atypical Antipsychotics Have Very Different Adverse Effect Profiles and Should Not Be Lumped Together--Reply
Gill et al.
Arch Intern Med 2006;166:586-587.
FULL TEXT  

Conventional vs. atypical antipsychotic medications.
Lee et al.
NEJM 2006;354:972-974.
FULL TEXT  

Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics
Aupperle
AM J ALZHEIMERS DIS OTHER DEMEN 2006;21:101-108.
ABSTRACT  

Implications of part d for mentally ill dual eligibles: a challenge for medicare.
Morden and Garrison
Health Aff (Millwood) 2006;25:491-500.
ABSTRACT | FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Sikand et al.
JAMA 2006;295:495-495.
FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Hammerstrom
JAMA 2006;295:496-496.
FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Gill et al.
JAMA 2006;295:495-496.
FULL TEXT  

Elderly Patients Show Elevated Mortality Risk on Atypicals
Rosack
Psychiatr. News 2005;40:1-36.
FULL TEXT  

Risk for Death with Antipsychotics in Patients with Dementia
JWatch Psychiatry 2005;2005:3-3.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2005;331:987-988.
FULL TEXT  

Antipsychotic Drugs in Dementia: What Should Be Made of the Risks?
Rabins and Lyketsos
JAMA 2005;294:1963-1965.
FULL TEXT